Riskstratifiering vid pulmonell arteriell hypertension - Ger bättre behandling och prognos – högspecialiserat omhändertagande vid universitetssjukhusen krävs
(2018) In Läkartidningen 115.- Abstract
Pulmonary arterial hypertension (PAH) is a progressive vascular disease, due to vasoconstriction and remodelling of pulmonary arteries. Survival has from diagnosis, if untreated, been found to be 1 to 2.8 years, depending on whether related to rheumatic disease or not. The ESC/ERS risk stratification tool provides a new approach to evaluate the clinical status of PAH patients. It supports a refined treatment strategy, based on risk assessment at diagnosis and early follow-up, with the aim to identify patients early and initiate, as well as adjust treatment individually, striving for the patients to remain in, or improve to low risk status, whereby survival is markedly improved.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/83d09630-fbf1-4210-abe7-80e7844268e9
- author
- Rådegran, Göran LU
- organization
- alternative title
- Riskstratification in pulmonary arterial hypertension - renders better treatment and prognosis at highly specialised centers
- publishing date
- 2018-10-15
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Läkartidningen
- volume
- 115
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:30325476
- scopus:85054898463
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- yes
- id
- 83d09630-fbf1-4210-abe7-80e7844268e9
- alternative location
- http://lakartidningen.se/Klinik-och-vetenskap/Kommentar/2018/10/Riskstratifiering-vid-pulmonell-arteriell-hypertension/
- date added to LUP
- 2018-10-30 11:58:30
- date last changed
- 2024-06-24 23:08:13
@article{83d09630-fbf1-4210-abe7-80e7844268e9, abstract = {{<p>Pulmonary arterial hypertension (PAH) is a progressive vascular disease, due to vasoconstriction and remodelling of pulmonary arteries. Survival has from diagnosis, if untreated, been found to be 1 to 2.8 years, depending on whether related to rheumatic disease or not. The ESC/ERS risk stratification tool provides a new approach to evaluate the clinical status of PAH patients. It supports a refined treatment strategy, based on risk assessment at diagnosis and early follow-up, with the aim to identify patients early and initiate, as well as adjust treatment individually, striving for the patients to remain in, or improve to low risk status, whereby survival is markedly improved.</p>}}, author = {{Rådegran, Göran}}, issn = {{0023-7205}}, language = {{swe}}, month = {{10}}, publisher = {{Swedish Medical Association}}, series = {{Läkartidningen}}, title = {{Riskstratifiering vid pulmonell arteriell hypertension - Ger bättre behandling och prognos – högspecialiserat omhändertagande vid universitetssjukhusen krävs}}, url = {{http://lakartidningen.se/Klinik-och-vetenskap/Kommentar/2018/10/Riskstratifiering-vid-pulmonell-arteriell-hypertension/}}, volume = {{115}}, year = {{2018}}, }